Drugs / Typhim Vi
Typhim Vi
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06630884 | Mar 2025 → Nov 2028 expected | post-traumatic stress disorder | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 1 | NCT03312699 | Sep 2017 → Dec 2023 | hepatitis A virus infection, influenza, typhoid fever | Stanford University | Completed | No outcome recorded |
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT05480800 | Sep 2022 → Sep 2024 | salmonellosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT05073003 | Oct 2021 → Jun 2025 | diarrheal disease | GlaxoSmithKline | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02429531 | Oct 2015 → Aug 2018 | immunodeficiency due to selective anti-polysaccharide antibody deficiency | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05919472 | Jul 2023 → Jul 2024 | iron deficiency anemia | Nicole Stoffel | Completed | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 0 | NCT05346302 Comparator | Feb → Dec 2022 | inflammatory disease | Texas A&M University | Completed | No outcome recorded |
| Phase 0 | NCT03048929 Comparator | Apr 2019 → Mar 2020 | post-traumatic stress disorder | University of California, San Francisco | Completed | No outcome recorded |
| Phase 0 | NCT03294564 Comparator | Jan → Dec 2018 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT05613205 Comparator | Nov 2022 → Dec 2023 | typhoid fever | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03956524 Comparator | Mar → Aug 2019 | typhoid fever | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02645032 Comparator | May 2016 → Feb 2017 | typhoid fever | International Vaccine Institute | Completed | No outcome recorded |
| Phase 1 | NCT03926455 Comparator | Mar 2016 → Feb 2017 | typhoid fever | Matrivax Research and Development Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02286544 Background | Oct 2014 → Dec 2015 | acute coronary syndrome, myocardial infarction | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2 | NCT03917654 Comparator | Apr 2019 → Jul 2021 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT01466387 Comparator | Nov 2011 → Apr 2012 | Japanese encephalitis, meningococcal meningitis, rabies, typhoid fever +1 | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT05745987 Comparator | Sep 2024 → Jun 2026 overdue | monkeypox | McMaster University | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Typhim Vi | “Following a 2-week baseline period, 210 healthy participants, aged 18-40 years, were administered either a Pneumococcal Polysaccharide vaccine (PPSV23), Typhoid Vi...” PMID 39245584 ↗ Sep 202412“Participants received TYPHIM VI as comparator intramuscularly on Day 1, and BOOSTRIX as comparator on Day 169.” NCT05613205 ↗ “Participants will receive the Typhim Vi® typhoid vaccine 0.5 ml single-dose” NCT05745987 ↗ |
| Known as | Salmonella typhi capsular polysaccharide vaccine | “Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA)...” NCT06630884 ↗2“Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine” NCT03048929 ↗ “Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine” NCT03294564 ↗ |
| Known as | Salmonella typhi vaccine | “Biological: TYPHIM Vi (Salmonella typhi vaccine)” NCT03917654 ↗ |
| Known as | Typhoid Vi Polysaccharide vaccine | “Following a 2-week baseline period, 210 healthy participants, aged 18-40 years, were administered either a Pneumococcal Polysaccharide vaccine (PPSV23), Typhoid Vi...” PMID 39245584 ↗ Sep 2024 |
| Known as | Typhoid VI Polysaccharide Vaccine Injectable Solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05745987 ↗ |
| Modality | Vaccine | “typhoid Vi polysaccharide vaccine” NCT01466387 ↗ |
| Route | Intramuscular | “as an intramuscular injection” NCT02286544 ↗ |